Genmab — November 2017
-
NEW: NCT03346135 Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT03346135?term=daratumumab+OR+ofatumumab&lupd_s=11%2F16%2F2017&rank=2
-
Quote: Darzalex is likely to be used in combination with Celgene's leading multiple-myeloma drug, Revlimid, which is slated to have sales of $12 billion in 2021. Genmab earns a tiered royalty on Darzalex sales, with the highest rate of 20% payable on net sales above $3 billion achieved in a calendar year. (08/16/17)
-
Plesner kørte sit eget lille ISS-studie ovre i Vejle med 4 pts, men med et interessant formål: Daratumumab is a new treatment for patients with myeloma. While many patients benefit from this treatment some do not and the mechanism(s) of failure are poorly understood. This study aims to clarify aspects of resistance to treatment with daratumumab in order to improve patient outcomes in the future.
-
Dette studie er nu afsluttet https://clinicaltrials.gov/ct2/show/NCT02419118?term=daratumumab&cntry1=EU%3ADK&rank=1
-
Mere grus i maskineriet for PD-1 og PD-L1: http://onkologisktidsskrift.dk/behandlinger/660-kraeftbehandlinger-medforer-reumatologiske-sygdomme.html
-
Ingen "roser uden alvorlige torne" i den terapi.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind